| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | KIN001-260 | GDSC1000 | pan-cancer | AAC | -0.041 | 0.2 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | -0.042 | 0.2 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.081 | 0.2 |
| mRNA | ML050 | CTRPv2 | pan-cancer | AAC | 0.05 | 0.2 |
| mRNA | BRD-K75293299 | CTRPv2 | pan-cancer | AAC | -0.099 | 0.2 |
| mRNA | Z-LLNle-CHO | GDSC1000 | pan-cancer | AAC | -0.065 | 0.2 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.073 | 0.2 |
| mRNA | Bicalutamide | FIMM | pan-cancer | AAC | -0.25 | 0.2 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | -0.049 | 0.2 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.04 | 0.2 |